Literature DB >> 33466440

Nanoparticles as Vaccines to Prevent Arbovirus Infection: A Long Road Ahead.

Gabriel Augusto Pires de Souza1,2, Raíssa Prado Rocha3, Ricardo Lemes Gonçalves4, Cyntia Silva Ferreira4, Breno de Mello Silva4, Renato Fróes Goulart de Castro1, João Francisco Vitório Rodrigues1, João Carlos Vilela Vieira Júnior1, Luiz Cosme Cotta Malaquias1, Jônatas Santos Abrahão2, Luiz Felipe Leomil Coelho1.   

Abstract

Arthropod-borne viruses (arboviruses) are a significant public health problem worldwide. Vaccination is considered one of the most effective ways to control arbovirus diseases in the human population. Nanoparticles have been widely explored as new vaccine platforms. Although nanoparticles' potential to act as new vaccines against infectious diseases has been identified, nanotechnology's impact on developing new vaccines to prevent arboviruses is unclear. Thus, we used a comprehensive bibliographic survey to integrate data concerning the use of diverse nanoparticles as vaccines against medically important arboviruses. Our analysis showed that considerable research had been conducted to develop and evaluate nanovaccines against Chikungunya virus, Dengue virus, Zika virus, Japanese encephalitis virus, and West Nile virus. The main findings indicate that nanoparticles have great potential for use as a new vaccine system against arboviruses. Most of the studies showed an increase in neutralizing antibody production after mouse immunization. Nevertheless, even with significant advances in this field, further efforts are necessary to address the nanoparticles' potential to act as a vaccine against these arboviruses. To promote advances in the field, we proposed a roadmap to help researchers better characterize and evaluate nanovaccines against medically important arboviruses.

Entities:  

Keywords:  arbovirus; experimental roadmap; nanoparticles; vaccine

Year:  2021        PMID: 33466440      PMCID: PMC7824877          DOI: 10.3390/pathogens10010036

Source DB:  PubMed          Journal:  Pathogens        ISSN: 2076-0817


  106 in total

Review 1.  Protein-based nanocarriers as promising drug and gene delivery systems.

Authors:  Ahmed O Elzoghby; Wael M Samy; Nazik A Elgindy
Journal:  J Control Release       Date:  2012-04-28       Impact factor: 9.776

2.  Nanoparticles target distinct dendritic cell populations according to their size.

Authors:  Vania Manolova; Anna Flace; Monika Bauer; Katrin Schwarz; Philippe Saudan; Martin F Bachmann
Journal:  Eur J Immunol       Date:  2008-05       Impact factor: 5.532

3.  Biomimetic approaches to modulating the T cell immune response with nano- and micro- particles.

Authors:  Stacey Demento; Erin R Steenblock; Tarek M Fahmy
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2009

4.  Differential uptake of nanoparticles by endothelial cells through polyelectrolytes with affinity for caveolae.

Authors:  Julia Voigt; Jon Christensen; V Prasad Shastri
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

Review 5.  Efficient delivery of therapeutic agents by using targeted albumin nanoparticles.

Authors:  Hasan Kouchakzadeh; Maryam Sadat Safavi; Seyed Abbas Shojaosadati
Journal:  Adv Protein Chem Struct Biol       Date:  2015-03-03       Impact factor: 3.507

6.  A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika.

Authors:  Jesse H Erasmus; Amit P Khandhar; Jeff Guderian; Brian Granger; Jacob Archer; Michelle Archer; Emily Gage; Jasmine Fuerte-Stone; Elise Larson; Susan Lin; Ryan Kramer; Rhea N Coler; Christopher B Fox; Dan T Stinchcomb; Steven G Reed; Neal Van Hoeven
Journal:  Mol Ther       Date:  2018-08-02       Impact factor: 11.454

7.  Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation.

Authors:  K Langer; M G Anhorn; I Steinhauser; S Dreis; D Celebi; N Schrickel; S Faust; V Vogel
Journal:  Int J Pharm       Date:  2007-06-23       Impact factor: 5.875

8.  Neuropathogenesis of Zika Virus in a Highly Susceptible Immunocompetent Mouse Model after Antibody Blockade of Type I Interferon.

Authors:  Darci R Smith; Bradley Hollidge; Sharon Daye; Xiankun Zeng; Candace Blancett; Kyle Kuszpit; Thomas Bocan; Jeff W Koehler; Susan Coyne; Tim Minogue; Tara Kenny; Xiaoli Chi; Soojin Yim; Lynn Miller; Connie Schmaljohn; Sina Bavari; Joseph W Golden
Journal:  PLoS Negl Trop Dis       Date:  2017-01-09

9.  A Modified mRNA Vaccine Targeting Immunodominant NS Epitopes Protects Against Dengue Virus Infection in HLA Class I Transgenic Mice.

Authors:  Claude Roth; Tineke Cantaert; Chloé Colas; Matthieu Prot; Isabelle Casadémont; Laurine Levillayer; Jessie Thalmensi; Pierre Langlade-Demoyen; Christiane Gerke; Kapil Bahl; Giuseppe Ciaramella; Etienne Simon-Loriere; Anavaj Sakuntabhai
Journal:  Front Immunol       Date:  2019-06-21       Impact factor: 7.561

10.  THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION.

Authors:  M Theiler; H H Smith
Journal:  J Exp Med       Date:  1937-05-31       Impact factor: 14.307

View more
  4 in total

Review 1.  Extracellular Polymeric Substances: Still Promising Antivirals.

Authors:  Raquel Bello-Morales; Sabina Andreu; Vicente Ruiz-Carpio; Inés Ripa; José Antonio López-Guerrero
Journal:  Viruses       Date:  2022-06-19       Impact factor: 5.818

Review 2.  An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19.

Authors:  Saman Yasamineh; Hesam Ghafouri Kalajahi; Pooneh Yasamineh; Yalda Yazdani; Omid Gholizadeh; Raheleh Tabatabaie; Hamed Afkhami; Fatemeh Davodabadi; Alireza Khanalipour Farkhad; Daryoush Pahlevan; Akram Firouzi-Amandi; Kazem Nejati-Koshki; Mehdi Dadashpour
Journal:  J Nanobiotechnology       Date:  2022-10-08       Impact factor: 9.429

Review 3.  A review of the antiviral activity of Chitosan, including patented applications and its potential use against COVID-19.

Authors:  Nisrein Jaber; Mayyas Al-Remawi; Faisal Al-Akayleh; Najah Al-Muhtaseb; Ibrahim S I Al-Adham; Phillip J Collier
Journal:  J Appl Microbiol       Date:  2021-07-26       Impact factor: 4.059

Review 4.  AMDV Vaccine: Challenges and Perspectives.

Authors:  Nathan M Markarian; Levon Abrahamyan
Journal:  Viruses       Date:  2021-09-14       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.